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Introduction 
Hypertension is a global public health concern. One of the key risk 
factors for cardiovascular disease, hypertension affects one billion 
people globally, and leads to heart attacks and strokes. The World 
Health Organisation estimates that complications of hypertension 
cause the deaths of 9.4 million people every year, accounting for at 
least 45% of deaths due to ischaemic heart disease and 51% of deaths 
due to cerebrovascular disease (WHO 2013). 
Hypertension is most prevalent in the African region (46%), with 
some variation by country: South Africa 42.4%, slightly higher in 
men (43.4%) than women (41.4%); Botswana 40.8%, Namibia 43.4%, 
Tanzania 39.2%, Zambia 40.1% and Zimbabwe 39%. 
In a South African survey an estimated 59% of black people visiting 
general practices had hypertension (Connor 2008), but these data 
are of limited use to determine actual care need, potential care costs, 
or burden of disease on the health care system because many South 
Africans report going without medical care due to living in resource 
limited communities (Kon 2008). 
Lifestyle modifications, including increased physical activity, and 
dietary change to limit kilojoules and reduce body fat, are known to 
reduce elevated blood pressure. 
• Regular aerobic physical activity such as brisk walking at least 
30 min/day, most days of the week, for a minimum of 150 
min/week has the potential to reduce systolic blood pressure 
by 4-9 mmHg (ACSM 2004);
• Maintaining normal body weight through limited kilojoule 
intake and adequate daily physical activity has the potential 
to reduce systolic blood pressure by 5-20 mmHg for every 10 
kg body mass reduction (ACSM 2004).
Current guidelines include a strong recommendation that lifestyle 
advice be offered to all patients with hypertension (NHFA 2016). A 
review undertaken by a South African research team, commissioned by 
the WHO, identified “what works” by way of community interventions 
for promoting healthy diet and physical activity (Anderson 2009). 
Home and community based interventions are likely to be more 
available and affordable for people with hypertension in resource-
limited communities than are supervised and practitioner led 
interventions. 
Physical activity is key component of lifestyle modification, and is a 
widely available, affordable intervention to reduce hypertension, yet 
in Africa levels of inactivity remain very concerning. South Africa is 
the country with the highest level of inactivity in Africa; 51% of South 
Africans report insufficient levels of exercise (WHO 2014). Inactivity in 
other African countries varies markedly, with considerable disparity 
between urban and rural dwellers, and between men and women. 
Hypertension is a silent, invisible killer that rarely causes 
symptoms…. Raised blood pressure is a serious warning sign that 
significant lifestyle changes are urgently needed. People need to 
know why raised blood pressure is dangerous, and how to take steps 
to control it.
 It contributes to the burden of heart disease, stroke and kidney 
failure and premature mortality and disability. It disproportionately 
affects populations in low- and middle-income countries where 
health systems are weak. 
Addressing behavioural risk factors, e.g. unhealthy diet, harmful use 
of alcohol and physical inactivity, can prevent hypertension. Tobacco 
use increases the risk of complications of hypertension. If no action 
is taken to reduce exposure to these factors, cardiovascular disease 
incidence, including hypertension, will increase. 
Integrated noncommunicable disease programmes implemented 
through a primary health care approach are an affordable and 
sustainable way for countries to tackle hypertension. (WHO 2013). 
Objective 
The objective of this review is to assess the effects of community and 
home-based exercise interventions for the prevention and treatment 
of hypertension. 
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Methods
Studies: Randomised, controlled trials (RCTs), using either non-
intervention or active controls, parallel and cross-over trials, and 
cluster RCTs examining the effects of exercise for the prevention or 
treatment of hypertension will be included. 
We will seek trials comparing:
• community or home-based exercise (resistance or aerobic) 
versus no exercise or wait-list control
• community or home-based exercise versus supervised 
exercise
• community or home-based exercise versus active control (ie: 
pharmacological management or dietary modification).
Studies in which hypertension is part of a broader disease picture, 
such as type 2 diabetes or cardiovascular disease, will be included if the 
effect of interventions on blood pressure are reported. 
Participants: Adults (18+ years) without regard to race or gender. 
Studies in children, and studies of hypertension or pre-eclampsia 
in pregnancy women will be excluded. Treatment trials will include 
participants with diagnosed hypertension of any severity and duration. 
We will use current Australian classification to grade hypertension 
as: Grade 1 (mild) 140-159/90-99 mmHg, Grade 2 (moderate) 160-
179/100-109 mmHg, Grade 3 (severe) 180+/110+ mmHg, and isolated 
systolic hypertension 140+/90- mmHg (NHFA 2016). Prevention trials 




• Systolic and diastolic blood pressure in millimetres of 
mercury (mmHg):
• Mean arterial pressure in millimetres of mercury (mmHg);
• Adverse events.
Note: These primary outcomes are criteria for inclusion. Studies that 
do not include a primary outcome measure of hypertension will be 
excluded. 
Secondary:
• Anti-hypertensive medication use;
• Categorical classification of hypertension;
• Standardised measures of cardiovascular fitness (eg: VO2 
peak, VO2 max);
• Body mass or composition (eg: BMI, waist circumference, 
waist to hip ratio);
• Other modifiable cardiovascular risk factors (eg: smoking);
• Medications known to alter cardiovascular function (eg: 
anti-retrovirals, glucocorticoids);
• Quality of life.
Data collection and extraction
Following a thorough search of all relevant electronic databases, 
titles and abstracts of potential trials will be reviewed, and a full 
manuscript retrieved for each study likely to meet review criteria. 
Data will be extracted from each eligible study. Because we anticipate 
a large number of studies will be included in this review, and the 
inclusion of studies in languages other than English, all investigators 
will contribute to data collection and extraction, and each task will 
be completed by at least two investigators acting independently. Any 
disagreements in data collection, extraction, and analyses will be 
resolved by consensus and reference to this protocol. 
These data will be extracted from the included trials and entered into 
RevMan 5:
1. trial characteristics including size and location of the trial, 
and source of funding;
2. characteristics of the study population including age and 
clinical presentation (ie: risk of hypertension, stage of 
hypertension);
3. characteristics of the therapy in all trial arms including type 
and duration of intervention;
4. risk of bias domains;
5. primary and secondary outcomes, reported as mean and 
standard deviation for continuous outcomes, and number of 
events for dichotomous outcomes. 
To avoid multiple outcome reporting, we will apply these rules to data 
extraction:
• Where outcomes are reported at several time points, we will 
extract the measure at the end of the intervention as the 
main outcome. Studies of similar duration will be analysed 
using end of intervention data only. We will also extract data 
at interim time points only when there is the opportunity to 
pool these data with trials of shorter durations, and we will 
clearly identify these data as being non-end-point data.
• Where trial authors report both final values and change from 
baseline values for the same outcome, we will extract final 
values.
• Where trial authors report analysis based on an intention-
to-treat (ITT) sample and another sample (e.g. per-
protocol), we will extract ITT-analysed data.
• If trial authors report an outcome using more than one 
standardised scale, we will extract data for that outcome 
once, according to an a priori determined hierarchy of scales.  
• For crossover trials, we will extract data only to the point 
of crossover, given the potential for carry-over effects of 
interventions to bias results following crossover.
Adverse events will be measured as the number of patients 
experiencing any adverse event, patients who withdrew or dropped 
out because of adverse events, and patients who experienced any 
serious adverse events. Serious adverse events are defined as events 
resulting in in-patient hospitalisation, prolongation of hospitalisation, 
persistent or significant disability, life-threatening events, or death.
If additional data are required, we will contact the trial authors to 
obtain these data. Where missing data are imputed or calculated (eg: 
standard deviations calculated from standard errors; imputed from 
graphs; last measure carried forward) we will report these adjustments 
in the characteristics of included studies. 
Analyses 
We will assess included trials for homogeneity of participants, 
interventions, and comparators, and pool data from clinically 
homogenous trials in meta-analyses. For each trial, we will present 
outcome data as point estimates, mean and standard deviation for 
continuous outcomes, and risk ratio (RR) with corresponding 95% 
confidence interval (CI) for dichotomous outcomes. 
Meta-analyses of continuous outcomes will be presented as weighted 
mean difference (WMD) of homogenous studies. When different scales 
are used to measure the same outcome, standardised mean difference 
(SMD) will be reported. Pooled dichotomous outcomes will be reported 
as omnibus RR. 
We will quantify inconsistency (heterogeneity) across studies using the 
I2 statistic, with a rough guide to interpretation as: 0% to 40% might 
not be important; 30% to 60% might represent moderate heterogeneity; 
50% to 90% may represent substantial heterogeneity; 75% to 100% 
considerable heterogeneity. If moderate to substantial heterogeneity 
is present in any pooled studies, we will investigate possible sub-
groupings post hoc. 
To identify possible publication bias, we will construct funnel plots if at 
least 10 studies are available for a meta-analysis of a primary outcome. 
We will assess the presence of small study bias in the meta-analyses by 
comparing random- and fixed-effects models. 
Typically, sensitivity analyses would be conducted to investigate the 
robustness of the intervention effects on subjective outcomes (eg: 
quality of life) relative to allocation concealment and participant 
blinding. In exercise intervention trials, participant blinding is almost 
impossible (ie: participants know whether they are exercising or not), 
examiner blinding may be difficult (ie: examiners may observe exercise 
training effects in participants and be able to infer to which groups 
they were allocated), and allocation concealment is unlikely to reduce 
these study limitations. If there are substantial differences in trial 
design or quality within meta-analyses, we will attempt sensitivity 
analyses, such as removing the poorer quality trials from an analysis to 
see if this changes overall treatment effects.
Interpretation 
Although hypertension is an independent predictor of cardiovascular 
disease risk, and lowering blood pressure reduces cardiovascular 
events and all-cause mortality, effective treatment targets have been 
ever changing and debated (NHFA 2016). Treatment effect sizes in 
this review will be discussed with reference to treatment targets in 
hypertension rather than any agreed minimum clinically important 
difference. 
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